Hint mode is switched on Switch off
For swift navigation between sections

Greenland Mines

PDF download

Choose all Reset all
Download Cancel
Organization name
Greenland Mines Ltd.
Country name
USA
Country of registration
USA
Industry
Pharmaceutical Preparation and Biotechnology
Public debt
-

Upgrade to Premium features

Cbonds consolidates global bond, stock, ETF and indices data into a single platform — so you can analyze faster, make informed investment decisions and outperform the market

Get access
Welcome to Cbonds

  • Full access to the largest bond database

    Bond parameters,
    prospectuses

  • Seamless
    Data export

    Analyze the data in the most efficient way

  • Bond pricing

    Current & historical quotes from 400+ stock exchanges & OTC market

  • Smart risk assessment

    Credit ratings, financial reports

Get access

Latest data on

Get access to the largest financial database

Try in 7-days Demo access

Free for company representative

  • Evaluate advanced analytical tools
  • Get full online access to the database
  • Try our powerful bond screener
  • Track bond prices from 400+ sources

Get access to the largest financial database

Representative of the company 7 days FREE trial

Professional access to the data

Private investor

Individual access

Quotes

Request sent
Access denied
Send request
Quotes provided by information providers are indicative in nature

Profile

Greenland Mines Ltd, formerly Klotho Neurosciences, Inc., is a natural resources company. The Company is focused is focused on the exploration and development of the Skaergaard Project. It operates with two operating divisions Natural Resources and Cell and Gene Therapy. The Natural Resources division is focused on the exploration and development of the Skaergaard Project in Southeast Greenland, which is undeveloped palladium, gold, and platinum deposits. It operates three Mineral Exploration Licenses (MEL): MEL 2007-01, MEL 2012-25, and MEL 2021-10. The Company holds, through its acquisition of Greenland Mines Corp., an 80% interest in, and option to acquire the remaining 20% of, the Skaergaard Project. The Cell and Gene Therapy division includes the Company's KLTO-202 primary indication for amyotrophic lateral sclerosis (ALS or Lou Gehrig’s Disease).

Awards

News

20/05/2026 Greenland Mines: Entry Into Material Agreement, Financial Statements And Exhibits
17/04/2026 Greenland Mines: Departure Of Directors Or Certain Officers; Election Of Directors; Appointment Of Certain Officers; Compensatory Arrangements Of Certain Officers, Financial Statements And Exhibits
11/03/2026 Klotho Neurosciences: – Amendments To Articles Of Incorporation, – Regulation Fd Disclosure, – Other Events, – Financial Statements And Exhibits
09/03/2026 Klotho Neurosciences Announces Rebranding to Greenland Mines Ltd and Change of Nasdaq Ticker Symbol to GRML Effective March 12, 2026
04/03/2026 Greenland Mines: Of This Form 8k/a, The Company Has Determined That The Acquired Assets Do Not Constitute A Business For Purposes Of Rule 305 Of Regulation Sx. Accordingly, No Financial Statements Or Pro Forma Financial Information Are Required Under Item 9.01 Of Form 8k
All organization news

Documentation

IFRS/US GAAP reports

2026
I q eng
2025
I q eng
II q eng
2024
I q eng
II q eng
III q eng
IV q eng
2023
I q eng
II q eng
III q eng
IV q eng
2022
I q eng
II q eng
III q eng
IV q eng
Show all Hide
Authorization required
You need to request access

Stocks

Public debt by currencies

Show more Hide

Codes

  • SIC
    2836 BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES)
  • CIK
    0001907223
  • EIN
    86-2727441
Registration is required to get access.